If TP53 mutants indeed enhance KMT2A activity through KMT2A partners such as MEN1, TP53-mutant leukemia including AEL may benefit from the recent development of highly potent and selective small molecules blocking the functionally critical interaction of KMT2A and Menin.146. The gene discussed is KMT2A; the disease is leukemia.